| Document |
Document Title |
|
WO/2020/224656A1 |
Provided are a substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the def...
|
|
WO/2020/227168A1 |
The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with th...
|
|
WO/2020/225569A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally s...
|
|
WO/2020/219935A1 |
Disclosed herein are methods to treatment of inflammatory and fibrotic progression, for example, idiopathic pulmonary fibrosis (IPF) with a dual inhibitor of soluble epoxide hydrolase inhibitors (sEH) and a secondary target. In particula...
|
|
WO/2020/216984A1 |
The present invention relates to the use of a composition for the treatment and/or prevention of the side-effects of radiotherapy and/or chemotherapy, preferably as a protective post-treatment composition, that is, the effect is produced...
|
|
WO/2020/212748A1 |
The invention relates to a phenylmethylpyrazolone compound and a method for producing same, said compound having a novel crystal form that corresponds to parameters determined by the method of powder X-ray diffraction analysis, wherein t...
|
|
WO/2020/212991A1 |
A method is disclosed for preparing pyrazole derivative 3-bromo- 5-methyl- 1-H- pyrazole- N-2-chloropyridine (compound of Formula I) by reacting of a compound of Formula II with halogen substituted pyridine optionally in the presence of ...
|
|
WO/2020/212253A1 |
1) A process for preparing Axitinib ( N-methyl-2-({3-[(E)-2-pyridin-2- ylethenyl]-lH-indazol-6-yl}sulfanyl)benzamide; compound of formula (l)) 2) A process for purifying the intermediate 2-((3-iodo-lH-indazol-6- yl)thio)-N-methylbenzamid...
|
|
WO/2020/215022A1 |
Disclosed herein are novel compounds that inhibit fructokinase (KHK or ketohexokinase) and the downstream metabolic effects mediated by fructose metabolism. Fructokinase inhibitors specifically block the metabolism of both dietary and en...
|
|
WO/2020/212530A1 |
The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.
|
|
WO/2020/214791A1 |
Provided is a method for the management of signs and symptoms of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, or ankylosing spondylitis in a patient in need thereof; for the management of acute pain or cancer rela...
|
|
WO/2020/210139A1 |
Compounds of formula I, that induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity are described herein.
|
|
WO/2020/210657A1 |
The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
|
|
WO/2020/210828A1 |
The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.
|
|
WO/2020/200209A1 |
Provided are an aromatic amine compound and a use thereof in the preparation of AR and BRD4 dual inhibitors and regulators. Specifically provided is the compound shown in formula I, said compound having dual inhibitory effects on AR and ...
|
|
WO/2020/198368A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2020/192588A1 |
The present invention relates to an alkylsulfamoyl indazole carboxamide derivative, a preparation method therefor, and a pharmaceutical use thereof. In particular, disclosed are a compound of formula (I) or a pharmaceutically acceptable ...
|
|
WO/2020/196660A1 |
Provided are: a cyclic butane compound production method comprising performing a [2+2] photocyclization reaction of an unsaturated compound in the presence of a compound represented by formula 1a or formula 1b; a photosensitizer; and a p...
|
|
WO/2020/192553A1 |
The present invention relates to a sulfonyl-substituted benzoheterocyclic formamide derivative, and a preparation method therefor and a medical use thereof. Specifically, a compound of formula (I) or a pharmaceutically acceptable salt, a...
|
|
WO/2020/198067A1 |
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I), including pharmaceutically acceptable salts, isotopic forms, tautomers and prodrugs thereof, wherein R1, R2, and R3 are as define...
|
|
WO/2020/188376A1 |
The present disclosure relates to a process for the synthesis of Fipronil which is a broad spectrum insecticide (I). The process of the present disclosure provides fipronil with a yield in the range of 75% to 90% and purity in the range ...
|
|
WO/2020/177534A1 |
The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also pr...
|
|
WO/2020/179910A1 |
The present invention provides a novel compound that can be used as an agricultural and horticultural agent, specifically as a pest controlling agent or a nematode controlling agent for agricultural and horticultural uses. The compound i...
|
|
WO/2020/177067A1 |
The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also pr...
|
|
WO/2020/175851A1 |
The present invention relates to: a benzoindazolone compound, or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diastereomer, tautomer, or prodrug thereof; and an intermediate thereof. A compound according to the prese...
|
|
WO/2020/173457A1 |
The present invention provides substituted pyrazole compounds, compositions containing same, and use thereof. The substituted pyrazole compounds comprise a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal...
|
|
WO/2020/175957A1 |
The present invention relates to a derivative compound having a pyrazole amide structure, an enantiomer thereof, or a pharmaceutically acceptable salt thereof. According to the present invention, the pyrazole amide derivative compound, t...
|
|
WO/2020/172609A1 |
The present invention provides novel compounds with increased plasma stability that modulate PAR1 signaling, and methods of using them. The present invention provides methods of using the novel PAR1 modulators for the treatment of a numb...
|
|
WO/2020/168149A1 |
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, ...
|
|
WO/2020/165062A1 |
Compounds of the formula (I) in which R1, R2, X, Y and Z have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
|
|
WO/2020/164993A1 |
The compound of formula, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising said compound and to methods of using said compound to combat and control pests such as insect, acarine...
|
|
WO/2020/163689A1 |
This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in nee...
|
|
WO/2020/163554A1 |
Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for examp...
|
|
WO/2020/161275A1 |
The present invention relates to novel, optionally substituted, N-benzyl-2- phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmac...
|
|
WO/2020/157771A1 |
The present invention relates to preparation of pyrazoles. This invention further relates to a continuous flow micro-total process system for preparation of celecoxib, a COX-2 selective non-steroidal anti-inflammatory drug, and analogs t...
|
|
WO/2020/155057A1 |
A crystal form X of 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-
5β-pregnan-20-one, a preparation method of said crystal form and an application thereof in preparing a drug for treatment of central nervous system disease.
|
|
WO/2020/158225A1 |
Provided is a novel antioxidant. An antioxidant according to the present invention contains a compound represented by formula (1) or a salt thereof. In formula (1), ring A and ring B may be the same or may differ from one another and are...
|
|
WO/2020/157652A2 |
This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to phar...
|
|
WO/2020/151687A1 |
Provided is an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by a general formula (I), or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivati...
|
|
WO/2020/154321A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula (AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/151686A1 |
Provided in the present invention are an N-heteroaryl sulfonamide derivative, the preparation and use thereof. The N-heteroaryl sulfonamide derivative is an N-heteroaryl sulfonamide compound shown in general formula (I) or general formul...
|
|
WO/2020/154034A1 |
The present invention features compositions and methods featuring CD82 for treating muscular dystrophies and related disorders. In one aspect, the invention provides a method of preserving or increasing muscle function in a dystrophic ce...
|
|
WO/2020/147739A1 |
The present invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to lysophosphatidic acid receptor antagonists and a preparation method therefor. The compounds of the present invention have high ...
|
|
WO/2020/150417A2 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/150265A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
|
|
WO/2020/150474A1 |
The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
|
|
WO/2020/150091A1 |
The present invention relates to Compounds of Formula I and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, X and A are as defined herein. The present invention also relates to compositions comprising at lea...
|
|
WO/2020/148760A1 |
The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.
|
|
WO/2020/148403A1 |
The present invention is directed to 5-membered heteroaryl compounds containing a hydroxamate moiety of Formula I, pharmaceutically acceptable salts or solvates thereof, and their use as sensitizers for chemotherapy of malignant tumors.
|
|
WO/2020/135513A1 |
The present invention relates to a compound serving as an IRAK inhibitor. Specifically, the present invention provides a compound, or a cis-trans-isomer, an optical isomer or raceme thereof, or a pharmaceutically acceptable salt, a prodr...
|
